CertaraCERT -0.59%65 EV-to-EBIT is 80.24 as of Jul. 12, 2026, which is 36% above its 10-year median of 58.91. GuruFocus rates CERT with a GF Score™ of 65/100 and a GF Value™ of $13.37 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 468 Healthcare Providers & Services companies, Certara ranks worse than 91.24% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Certara's Enterprise Value is $1,203.9 Mil.
Certara's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $15.0 Mil. Therefore, Certara's EV-to-EBIT for today is 80.24.
The historical rank and industry rank for Certara's EV-to-EBIT or its related term are showing as below:
CERT'
s EV-to-EBIT Range Over the Past 10 Years
Min: -240.08 Med: 58.91 Max: 558.64
Current: 80.24
During the past 8 years, the highest EV-to-EBIT of Certara was 558.64. The lowest was -240.08. And the median was 58.91.
CERT's EV-to-EBIT is ranked worse than 91.24% of 468
companies
in the Healthcare Providers & Services industry
Industry Median: 15.815
vs CERT: 80.24
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Certara's Enterprise Value for the quarter that ended in Mar. 2026 was $1,024.7 Mil.
Certara's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Certara EV-to-EBIT Related Terms
Certara EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Certara's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Certara's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Certara EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Certara's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Certara's EV-to-EBIT falls into.
Certara's current Enterprise Value is $1,203.9 Mil.
Certara's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Certara (CERT) has a EV-to-EBIT of 80.24 as of Jul. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Certara and its competitors. This is 36% above median its historical median of 58.91. According to the industry distribution chart, Certara ranks #427 out of 468 companies in the Healthcare Providers & Services industry, placing it in the top 91.2%.
Is Certara's EV-to-EBIT too high?
Certara's current EV-to-EBIT of 80.24 is 36% above median its 10-year median of 58.91. The Healthcare Providers & Services industry median EV-to-EBIT is 15.82. Certara's value of 80.24 is 407.4% above this industry median. Based on the distribution chart, Certara ranks #427 out of 468 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Certara has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Certara's EV-to-EBIT compare to TALK and GDRX?
According to the Healthcare Providers & Services industry distribution chart, Certara ranks #427 out of 468 companies for EV-to-EBIT. This places Certara in the lower half of its industry. The industry median EV-to-EBIT is 15.82. Certara's value of 80.24 is 407.4% above this benchmark. While the company's 10-year median is 58.91 vs. the industry median of 15.82, Certara has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.82, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Certara's current EV-to-EBIT of 80.24 is 407.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Certara and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Certara's current EV-to-EBIT is 80.24, which is 36% above median its own 10-year median of 58.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Certara stock overvalued right now?
Based on GuruFocus' analysis, Certara (CERT) is currently considered Possible Value Trap. The stock's GF Value™ is $13.37, compared to a current price of $6.77 — trading 49.4% below its estimated fair value. The current EV-to-EBIT is 80.24, which is 36% above median its 10-year median of 58.91 and 407.4% above the Healthcare Providers & Services industry median of 15.82. Certara's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Certara (CERT), the current EV-to-EBIT is 80.24 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Certara (CERT) Overvalued in 2026?
Based on GuruFocus' analysis, Certara stock appears to be undervalued.
The current stock price of $6.77 is trading 49.4% below its estimated GF Value™ of $13.37.
GuruFocus considers Certara to be Possible Value Trap.
Key valuation signals for CERT:
EV-to-EBIT: 80.24 (36% above median its 10-year median of 58.91)
GF Value™: $13.37 vs. price of $6.77 (49.4% below fair value)
Industry Position: 407.4% above the Healthcare Providers & Services median (#427 of 468)
No single metric tells the full story. See the CERT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
65GF Score
Get the complete analysis for CERT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERT has been successfully added to your 
